Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
The Lancet Oncology（2022）
摘要
Merck Sharp & Dohme, a subsidiary of Merck & Co.
更多查看译文
关键词
pembrolizumab,lung cancer,adjuvant therapy,placebo,non-small-cell,triple-blind
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要